Form 4: TriSalus Life Sciences CFO James Emmett Young Acquires 6,000 Shares

James Emmett Young, CFO of TriSalus Life Sciences, purchased 6,000 shares of common stock at $5.65 per share on February 5, 2025.

Summary

• On February 5, 2025, James Emmett Young, the Chief Financial Officer of TriSalus Life Sciences, Inc. (TLSI), acquired 6,000 shares of common stock.
• The purchase price was $5.65 per share.
• Following the transaction, Mr. Young directly owns 21,726 shares of common stock.
• He also indirectly owns 30,000 shares through the Kathleen A. Young Living Trust, for which he serves as the sole trustee.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. The CFO's purchase suggests confidence, but it's a relatively small transaction.

Positives

• The CFO's purchase of shares could be interpreted as a positive signal, indicating confidence in the company's future prospects.

Industry Context

Form 4 filings are standard disclosures required by the SEC when corporate insiders, like officers and directors, buy or sell their company's stock. These filings provide transparency into insider transactions and can be closely watched by investors for signals about a company's prospects.

Stakeholder Impact

• Shareholders may view the CFO's stock purchase as a positive sign.

Key Dates

Keywords

TriSalus Life Sciences, James Emmett Young, CFO, stock purchase, Form 4, TLSI, beneficial ownership